Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Yong Ha Chi"'
Autor:
Tae Hwan Kim, Soo Heui Paik, Yong Ha Chi, Jürgen B. Bulitta, Da Young Lee, Jun Young Lim, Seung Eun Chung, Chang Ho Song, Hyeon Myeong Jeong, Soyoung Shin, Beom Soo Shin
Publikováno v:
Pharmaceutics, Vol 10, Iss 4, p 174 (2018)
The aim of the present study was to assess the regional absorption of fimasartan by an improved in situ absorption method in comparison with the conventional in situ single-pass perfusion method in rats. After each gastrointestinal segment of interes
Externí odkaz:
https://doaj.org/article/2141e5c71e764dd29f4209dff463c4b8
Publikováno v:
Food and Chemical Toxicology. 115:375-384
Fimasartan (FMS), an angiotensin II receptor antagonist, is metabolized to FMS S-oxide, FMS N-glucuronide, oxidative desulfurized FMS (BR-A-557), and hydroxy-n-butyl FMSs. The purpose of this study was to characterize enzymes involved in NADPH-depend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af02ae4eab8adc026e92fb683d3a27a
https://doi.org/10.1016/j.fct.2018.03.036
https://doi.org/10.1016/j.fct.2018.03.036
Publikováno v:
Biological & Pharmaceutical Bulletin. 40:992-1001
The pharmacological profile of fimasartan, [2-n-butyl-5-dimethylamino-thiocarbonyl-methyl-6-methyl-3-{[2-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-pyrimidin-4(3H)-one, a new non-peptide angiotensin type 1 (AT1)-selective angiotensin receptor antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db395a19c40e7ee08171734b5c7a4ec3
https://doi.org/10.1248/bpb.b16-00987
https://doi.org/10.1248/bpb.b16-00987
Autor:
Beom Soo Shin, Jun Young Lim, Soo Heui Paik, Chang Ho Song, Jürgen B. Bulitta, Yong Ha Chi, Da Young Lee, Hyeon Myeong Jeong, Seung Eun Chung, Tae Hwan Kim, Soyoung Shin
Publikováno v:
Pharmaceutics, Vol 10, Iss 4, p 174 (2018)
Pharmaceutics
Volume 10
Issue 4
Pharmaceutics
Volume 10
Issue 4
The aim of the present study was to assess the regional absorption of fimasartan by an improved in situ absorption method in comparison with the conventional in situ single-pass perfusion method in rats. After each gastrointestinal segment of interes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8cdb915f765c84faba15835d043319
http://www.mdpi.com/1999-4923/10/4/174
http://www.mdpi.com/1999-4923/10/4/174
Autor:
Young-Ran Yoon, Soo Jin Oh, Yong Ha Chi, Chang Seon Ryu, Jae-Kyung Jung, Dong-Hyun Kim, Young Jae Choi, Sang Kyum Kim, Soo Heui Paik, Kwon-Bok Kim, Ki Ho Lee, Ji-Yoon Lee
Publikováno v:
Xenobiotica. 46:40-51
1. The metabolites of fimasartan (FMS), a new angiotensin II receptor antagonist, were characterized in human liver microsomes (HLM) and human subjects. 2. We developed a method for a simultaneous quantitative and qualitative analysis using predictiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a646b7c6ee3a41a7230574aa52cec4a
https://doi.org/10.3109/00498254.2015.1047429
https://doi.org/10.3109/00498254.2015.1047429
Autor:
Eun-Sook Jeong, Hyo-Ji Kim, Yong Ha Chi, Kwang Hee Kim, Soo Heui Paik, Jae-Gook Shin, Ho-Jung Shin, Yang-Weon Kim, Dong-Hyun Kim
Publikováno v:
Xenobiotica. 45:10-18
1. Fimasartan is an angiotensin receptor II antagonist used to treat patients with hypertension. This drug is mainly excreted into bile as either the parent compound or a glucuronide conjugate. In this study, we examined the glucuronidation of fimasa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b0954ba7fa484b7fb6abeae905df33
https://doi.org/10.3109/00498254.2014.942810
https://doi.org/10.3109/00498254.2014.942810
Autor:
Eunsook Ma, Soyoung Shin, Sun Dong Yoo, Sang Hoon Joo, Mohammad Bashir, Beom Soo Shin, Jin Ho Choi, Joo Han Lee, Jürgen B. Bulitta, Soo Heui Paik, Hyuk Joon Choi, Yong Ha Chi, Tae Hwan Kim
Publikováno v:
Xenobiotica. 44:913-925
1. The objectives of this study were to evaluate the pharmacokinetics and metabolism of fimasartan in rats. 2. Unlabeled fimasartan or radiolabeled [(14)C]fimasartan was dosed by intravenous injection or oral administration to rats. Concentrations of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126d8fe91d77f95ac22b96348f367c5e
https://doi.org/10.3109/00498254.2014.915359
https://doi.org/10.3109/00498254.2014.915359
Autor:
Byoung Wook Yoo, Nam Seok Han, Soo Heui Paik, Kyung-Tae Lee, Jae Yeol Lee, Je Hak Kim, Yong Ha Chi, Gi Hyun Kwon, Min Ji Choi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:4540-4546
As a development strategy for backups of Fimasartan (1), a comparative molecular similarity indices analysis (CoMSIA) of a set of sixty-five 5-(biphenyl-2-yl)-1H-tetrazole derivatives has been performed to find out the pharmacophore elements for angi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c3712e059356a3824631965dc733b6
https://doi.org/10.1016/j.bmcl.2013.06.041
https://doi.org/10.1016/j.bmcl.2013.06.041
Autor:
Cornelia B. Landersdorfer, Tae Hwan Kim, Jürgen B. Bulitta, Yong Ha Chi, Soo Heui Paik, Rajbharan Yadav, Yuanyuan Jiao, Beom Soo Shin, Soyoung Shin
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 107
Fimasartan is a novel angiotensin II receptor blocker. Our aims were to characterize the time-course of the antihypertensive activity of fimasartan via a new population pharmacokinetic/pharmacodynamic model and to define its optimal dose range. We si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a117a560059b0eb9b53e2183859389
https://pubmed.ncbi.nlm.nih.gov/28599987
https://pubmed.ncbi.nlm.nih.gov/28599987
Autor:
Joo Han Lee, Soo Heui Paik, Ji Han Kim, Sang Lin Kim, Howard Lee, Yong Ha Chi, Hyun Kwang Tan, Byoung Wook Yoo
Publikováno v:
American Journal Cardiovascular Drugs. 11:335-346
Fimasartan (BR-A-657) is a novel, non-peptide angiotensin II receptor antagonist with a selective type I receptor blockade effect. Two first-in-human studies investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682035b38b33a2eb97eb94b8a549f211
https://doi.org/10.2165/11593840-000000000-00000
https://doi.org/10.2165/11593840-000000000-00000